Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Fineline Cube May 15, 2026
Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Fineline Cube May 15, 2026
Company Deals

Biocytogen Pharmaceuticals Enters Agreement with Myricx Bio for ADC Development

Fineline Cube Sep 8, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody evaluation, option, and...

Company Deals

Danaher Partners with Beijing’s Changping District to Accelerate Science and Technology Innovation Center

Fineline Cube Sep 8, 2023

US-headquartered Danaher (NYSE: DHR), a Fortune 500 science and technology innovator, has entered into a...

Policy / Regulatory

Chongqing Unveils Three-Year Public Health Action Plan Draft for Public Feedback

Fineline Cube Sep 8, 2023

The health commission of Chongqing province has released the “Chongqing Public Health Capacity Improvement Three-year...

Company Drug

Immunofoco’s IMC008 Earns Orphan Drug Designation for Pancreatic Cancer from FDA

Fineline Cube Sep 8, 2023

Suzhou-based cell therapy developer Immunofoco has announced that it has received orphan drug designation (ODD)...

Company Drug

Shanghai Haihe Pharmaceutical’s Glumetinib Filed for Marketing in Japan for NSCLC Treatment

Fineline Cube Sep 8, 2023

Shanghai Haihe Pharmaceutical Co., Ltd has announced the filing for marketing approval in Japan for...

Company

Eminence Biotechnology Launches Fully Operational Cell Culture Media Facility in Suzhou

Fineline Cube Sep 8, 2023

China-based Eminence Biotechnology (Suzhou) Co., Ltd. has announced the full operation of its state-of-the-art cell...

Company Medical Device

LIQUIK Study Interim Results to Showcase Lucence’s Liquid Biopsy Advancements at WCLC 2023

Fineline Cube Sep 8, 2023

Precision medicine specialist Lucence, with a presence in Suzhou, Hong Kong, and Palo Alto, California,...

Company Drug

Luye Pharma’s Botawei Receives NMPA Approval for Breast Cancer Treatment

Fineline Cube Sep 8, 2023

Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...

Company Deals

ClouDr Partners with Hong Kong Magicure Medical Center to Enhance Cross-Border Medical Access

Fineline Cube Sep 8, 2023

Hangzhou Kang Ming Information Technology Co., Ltd, known as “ClouDr” (HKG: 9955), has entered into...

Company Medical Device

Mindray Launches TE Air Wireless Handheld Ultrasound Solution in the US Market

Fineline Cube Sep 8, 2023

China-based global device giant Mindray (SHE: 300760) has announced the market launch of its TE...

Company

MSD Plans to Introduce Over 50 New Drugs and Vaccines to China in the Next Five Years

Fineline Cube Sep 8, 2023

Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK), through its China R&D president Li Zhengqing,...

Company Deals R&D

Novo Nordisk and Broad Institute Collaborate on Diabetes and Cardiometabolic Research

Fineline Cube Sep 7, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a collaboration with the US academic...

Company Drug

Janssen’s Rybrevant Combo Meets Primary Endpoint in Advanced NSCLC Study

Fineline Cube Sep 7, 2023

Janssen, a subsidiary of Johnson & Johnson (J&J; NYSE: JNJ), has released an update on...

Company Policy / Regulatory

FDA Addresses Looming Migraine Treatment Shortage with Tonix Pharmaceuticals Commitment

Fineline Cube Sep 7, 2023

The US Food and Drug Administration (FDA) is actively engaging with pharmaceutical companies to address...

Company Drug

Henan Zhongshuai’s Dexmethylphenidate Hydrochloride Capsules Target Priority Review for Pediatric ADHD

Fineline Cube Sep 7, 2023

Henan Zhongshuai Pharmaceutical Co., Ltd., a China-based pharmaceutical company, is poised to secure priority review...

Company Drug

Amneal Pharmaceuticals Receives China Approval for Sevelamer Carbonate

Fineline Cube Sep 7, 2023

US-based Amneal Pharmaceuticals Inc. (NYSE: AMRX) has announced that it has received approval from the...

Company Drug

CSPC Pharmaceutical’s Narlumosbart Approved by NMPA for Bone Giant Cell Tumors

Fineline Cube Sep 7, 2023

CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its subsidiary, Shanghai JMT Biotechnology Co.,...

Company Drug

Jiangsu Hengrui’s HER2-Targeted ADC SHR-A1811 Aims for CDE’s BTD Status

Fineline Cube Sep 7, 2023

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its HER2 targeted antibody-drug...

Policy / Regulatory

NMPA Drafts Guidelines for Supervising Online Drug Exchange Platforms

Fineline Cube Sep 7, 2023

The National Medical Products Administration (NMPA) has released draft “Online Third-party Drug Exchange Platforms Inspection...

Company Drug

Genentech Files for FDA Approval of Crovalimab for PNH, Challenging Soliris

Fineline Cube Sep 7, 2023

Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has submitted its anti-C5 investigational drug, crovalimab,...

Posts pagination

1 … 477 478 479 … 666

Recent updates

  • Alibaba Health Reports Strong FY2026 Results with 35.2% Profit Growth and Launches Medical LLM “H+”
  • Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration
  • China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations
  • Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma
  • AstraZeneca Reports Positive Phase III VOLGA Interim Results for Imfinzi-Based Combinations in Muscle-Invasive Bladder Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Digital

Alibaba Health Reports Strong FY2026 Results with 35.2% Profit Growth and Launches Medical LLM “H+”

Company Drug

Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.